Turner Syndrome

1. Overview and Epidemiology
2. Cytogenetics and Variants
3. Physical Features
4. Cardiovascular Complications
5. Gonadal Dysgenesis and Fertility
6. Growth and Growth Hormone Therapy
7. Cognitive and Behavioral Profile
8. Estrogen Replacement Therapy
9. Long-Term Monitoring and Surveillance
10. Key Research Papers
11. Connections

Overview and Epidemiology

Turner syndrome (also called Monosomy X) is a chromosomal condition that affects females exclusively, arising from the complete or partial absence of one of the two X chromosomes normally present in every female cell. It is the most common sex chromosome abnormality in females, occurring in approximately 1 in 2,500 female live births. In the United States an estimated 70,000–80,000 women are living with the condition.

The syndrome is remarkably lethal in utero: roughly 99% of 45,X conceptions spontaneously abort, making it one of the most lethal chromosomal abnormalities ever conceived. Only those fetuses that retain enough functional cells survive to term, which is why the clinical spectrum seen at birth represents the fortunate minority of an intrinsically severe abnormality.

The condition was first described by American endocrinologist Henry Turner in 1938, when he reported a cohort of women with short stature, sexual infantilism, cubitus valgus, and webbed neck. The underlying chromosomal cause — loss of an entire X chromosome — was not identified until 1959 by Charles Ford and colleagues using newly developed karyotyping techniques.

The hallmark features are short stature, gonadal dysgenesis, infertility, and cardiovascular malformations. Intelligence is usually in the normal range. There is no ethnic or racial predilection, and unlike trisomies such as Down syndrome, Turner syndrome is not associated with advanced maternal age — the chromosomal loss occurs with roughly equal probability at any maternal age.

Back to Table of Contents

Cytogenetics and Variants

Turner syndrome is not a single chromosomal event but a family of karyotypic abnormalities, all sharing functional haploinsufficiency of X-linked genes that normally escape X-inactivation.

• Classic 45,X (Monosomy X): Approximately 45% of Turner syndrome cases carry a single X chromosome with no second sex chromosome at all. In roughly 70% of these cases the missing chromosome is the paternal X, indicating that the error most frequently arises during paternal meiosis or early post-zygotic division. There is no maternal age effect.
• Mosaic 45,X/46,XX: Seen in 15–20% of cases. A proportion of cells carry a normal 46,XX karyotype alongside a monosomic 45,X line. The phenotype is typically milder; some mosaic individuals experience spontaneous puberty, and 2–5% conceive naturally.
• Structural X abnormalities (~40%): The most common structural variant is isochromosome Xq (i(Xq)) — duplication of the long arm with loss of the short arm. Other variants include ring chromosome X, terminal deletions of the short arm (Xp), and translocations. Loss of the short arm consistently causes short stature and typical Turner features because it removes one copy of the SHOX gene (short stature homeobox gene) located in the pseudoautosomal region 1 (PAR1) of the X chromosome.

SHOX haploinsufficiency underlies the short stature and skeletal dysplasia seen in virtually all Turner variants. SHOX normally escapes X-inactivation; losing one copy disrupts chondrocyte proliferation and enchondral bone growth. Importantly, SHOX haploinsufficiency also causes short stature in Leri–Weill dyschondrosteosis, confirming its direct role.

Karyotyping from peripheral blood lymphocytes (minimum 30 cells analyzed) is the diagnostic standard. Prenatal diagnosis is increasingly made via cell-free fetal DNA (cfDNA) screening, confirmed by amniocentesis or chorionic villus sampling.

Back to Table of Contents

Physical Features

Turner syndrome has a recognizable but variable physical phenotype. Not every feature is present in every individual, and mosaic cases can be remarkably subtle.

• Short stature: The most consistent feature. Untreated adult height averages approximately 143 cm (4 feet 8 inches) in Western European populations, roughly 20 cm below the female average. Height loss begins gradually in early childhood and accelerates at the expected age of the adolescent growth spurt, which is absent.
• Webbed neck (pterygium colli): Neck skin folds extending from the mastoid to the acromion, caused by resolution of a fetal nuchal cystic hygroma. Present in about 40–50% of cases.
• Low posterior hairline and low-set ears: Remnants of the resolved nuchal hygroma.
• Lymphedema: Puffy hands and feet at birth, often the presenting sign in a newborn girl. Results from impaired lymphatic development secondary to the fetal cystic hygroma.
• Shield chest: Broad, flat chest with widely-spaced nipples — a classic but not universal finding.
• Cubitus valgus: Increased carrying angle at the elbow; often the feature that prompts referral in older children.
• Short fourth metacarpal: The "Drummond metacarpal sign" — shortening of the fourth (and sometimes fifth) metacarpal, visible on hand X-ray.
• Multiple pigmented nevi, nail dysplasia, high arched palate, micrognathia, scoliosis.

Structural abnormalities of internal organs are common: bicuspid aortic valve in ~30%, coarctation of the aorta in ~10%, and horseshoe kidney in 10–15%. These require dedicated imaging at diagnosis, not just clinical examination.

Back to Table of Contents

Cardiovascular Complications

Cardiovascular disease is the leading cause of premature death in Turner syndrome, accounting for a two- to three-fold increase in standardized mortality compared with the general female population. Women with Turner syndrome must receive lifelong cardiac surveillance.

The most common structural defect is bicuspid aortic valve (BAV), present in approximately 30% of individuals. BAV predisposes to aortic stenosis, regurgitation, and — critically — progressive dilation of the ascending aorta. Coarctation of the aorta occurs in ~10% and independently raises blood pressure and aortic wall stress. Partial anomalous pulmonary venous return is also more prevalent than in the general population.

Aortic dissection is the most feared complication. It can occur even with only mild aortic dilation and at younger ages than in other aortic syndromes. Key risk factors include hypertension, BAV, coarctation, and — importantly — pregnancy. The aortic size index (ASI), calculated as aortic root diameter divided by body surface area, is the preferred metric because Turner women tend to have small BSA; an ASI > 2.5 cm/m² signals elevated dissection risk. Reported dissection mortality ranges from 50–65%.

MRI of the thoracic aorta (not echocardiography alone, which underestimates ascending aortic dimensions in Turner syndrome) is the standard surveillance modality. Estrogen replacement does not fully protect against aortic dilation. Current guidelines recommend cardiac MRI at diagnosis and every 5–10 years thereafter, with more frequent imaging when BAV or dilation is present. Elective surgical repair thresholds vary by guideline but generally align with BAV-specific aortic aneurysm criteria rather than Marfan thresholds.

Back to Table of Contents

Gonadal Dysgenesis and Fertility

Ovarian failure is nearly universal in classic 45,X Turner syndrome. In utero, ovarian follicles form normally but undergo accelerated atresia; by birth or early childhood the ovaries have been replaced by streak gonads — thin fibrous bands of connective tissue incapable of producing estrogen or maturing eggs.

The hormonal consequence is hypergonadotropic hypogonadism: the pituitary senses the absence of ovarian estrogen and releases very high levels of FSH and LH, which remain persistently elevated while estradiol remains very low. This pattern, often detected on newborn screening or at the expected time of puberty, is a reliable biochemical marker.

Primary amenorrhea occurs in approximately 90% of 45,X women. The 10% who experience spontaneous puberty are almost exclusively mosaic (45,X/46,XX) individuals with residual functional ovarian tissue. Of those who menstruate spontaneously, premature ovarian insufficiency (POI) eventually develops in the large majority.

Fertility options:

• Donor egg IVF is the most reliable path to parenthood. Because the uterus is structurally normal and responds well to estrogen priming, success rates with donor eggs are comparable to those in women with other causes of POI. This is the recommended option for most Turner women.
• Oocyte cryopreservation may be offered to mosaic girls with documented ovarian reserve, ideally before further follicle depletion occurs.
• Spontaneous conception (2–5% of mosaic cases): These pregnancies carry a high rate of miscarriage and an elevated risk of chromosomally abnormal offspring; genetic counseling is essential.

Cardiac risk during pregnancy is substantial — aortic dissection risk increases during the hemodynamic stress of pregnancy. All Turner women considering pregnancy require pre-conception cardiac MRI and multidisciplinary assessment. Those with BAV, aortic dilation, or coarctation may be advised against carrying a pregnancy.

Back to Table of Contents

Growth and Growth Hormone Therapy

Short stature is the single most consistent feature of Turner syndrome across all karyotypic variants. The mean untreated adult height in Western populations is approximately 143 cm (± 7 cm), roughly 20 cm below the female population average. Height deficit arises from SHOX haploinsufficiency compounded by the absence of the pubertal estrogen-driven growth spurt.

Recombinant human growth hormone (rhGH) therapy is the standard of care and is FDA-approved specifically for Turner-associated short stature. Turner girls are not classically GH deficient — they have normal or low-normal GH secretion — but are GH-responsive because GH receptor signaling downstream of SHOX is intact.

Key practical points:

• Start early: Treatment is typically initiated between ages 2 and 5 years, as soon as height begins to fall off the normal growth curve. Earlier start correlates with greater final height gain.
• Dosing: Standard doses are higher than those used for GH deficiency (0.35–0.375 mg/kg/week, given daily subcutaneously).
• Oxandrolone adjunct: Low-dose oxandrolone (anabolic steroid, 0.03–0.05 mg/kg/day) added from about age 9 years provides an additional ~2–3 cm of final height over GH alone, without significant virilization at these doses.
• Duration: GH is continued until near-final height (bone age approximately 14–15 years) or until growth velocity falls below 2 cm/year.
• Outcome: With early, optimized treatment, final height gain of approximately 7–10 cm above untreated prediction is achievable. Most treated women reach approximately 150–152 cm.

GH therapy at standard doses has not been associated with significant adverse effects in Turner syndrome. Glucose metabolism should be monitored, given the baseline insulin resistance present in the condition.

Back to Table of Contents

Cognitive and Behavioral Profile

Turner syndrome is not associated with intellectual disability. The majority of affected women have intelligence in the normal range, with a mean full-scale IQ typically between 90 and 100. Most complete secondary and post-secondary education, hold employment, and live independently.

However, a consistent and well-characterized specific cognitive profile distinguishes Turner syndrome from other conditions and from the general female population:

• Relative weaknesses: Visuospatial processing, nonverbal memory, mental rotation, arithmetic and mathematical reasoning, executive function (planning, cognitive flexibility), and processing speed.
• Relative strengths: Verbal ability, reading, phonological processing, and verbal memory. Many Turner women have notably strong social-verbal skills.

Attention difficulties are common; the rate of ADHD diagnosis is elevated compared with age-matched peers. Anxiety disorders are also more prevalent, and some women describe difficulties with social cognition and interpreting social cues — though a formal autism spectrum diagnosis is uncommon.

The cognitive profile is thought to reflect the haploinsufficiency of X-linked genes that normally contribute to visuospatial and executive networks — in particular, the paternal X chromosome (which is more often the missing one) may carry imprinted genes influencing social cognition and frontal-lobe function.

Practical implications: neuropsychological testing at school entry, targeted learning-support for math and visual tasks, and treatment of ADHD and anxiety when present are the cornerstones of cognitive management. Cognitive difficulties are not a reason to lower educational expectations.

Back to Table of Contents

Estrogen Replacement Therapy

Because approximately 90% of Turner women do not undergo spontaneous puberty, estrogen replacement therapy (ERT) is essential — both to induce the physical changes of puberty and to prevent the long-term consequences of estrogen deficiency (osteoporosis, cardiovascular risk, cognitive effects, and impaired quality of life).

When to start: Current guidelines recommend initiating low-dose estrogen at approximately age 11–12 years, timed to coincide with the normal onset of puberty in the general population. Delaying past age 14 is associated with reduced bone accrual and psychosocial disadvantage.

How to initiate: Treatment begins with the lowest available dose of transdermal estradiol (patch or gel, preferred over oral estrogen for its more physiological pharmacokinetics and avoidance of first-pass hepatic effects). The dose is gradually increased over 2–3 years, mimicking the slow rise of estradiol through normal puberty. Rushing induction compromises final adult height by advancing bone age prematurely.

Maintenance phase: Once puberty induction is complete (typically by age 15–16), cyclic combined estrogen-progestogen is prescribed to produce regular withdrawal bleeds and prevent endometrial hyperplasia. The uterus responds normally to hormonal cycling.

Goals of ERT beyond puberty:

• Breast development, pubic and axillary hair growth, and uterine development sufficient to sustain a donor-egg pregnancy.
• Bone mineral density accrual and maintenance (prevents osteoporosis).
• Cardiovascular risk reduction (low estrogen is a major risk factor for premature atherosclerosis).
• Quality of life, libido, mood, and cognitive function.

ERT is not a fertility treatment — it does not restore ovarian function. Treatment should be maintained until the typical age of natural menopause (~51 years). Premature discontinuation is associated with accelerated bone loss and increased cardiovascular and cognitive risk. ERT is distinct from menopausal hormone therapy in that it replaces what was never present, not what was lost.

Back to Table of Contents

Long-Term Monitoring and Surveillance

Turner syndrome is a lifelong condition requiring structured, multidisciplinary surveillance. Many complications emerge or worsen in adulthood and are preventable or manageable with timely detection. Transition from pediatric to adult care is a critical and often poorly executed step — women should be transferred to an adult endocrinologist familiar with Turner syndrome, not simply discharged.

Annual surveillance should include:

• Blood pressure: Hypertension is common (up to 50% of adults) even without coarctation, and is the most modifiable risk factor for aortic dissection.
• Thyroid function (TSH, free T4): Autoimmune thyroiditis (Hashimoto's) occurs in 15–30% of women with Turner syndrome — a dramatically elevated rate compared with the general population.
• Hearing: Sensorineural hearing loss is progressive and affects up to 60–90% of adults. Annual audiologic evaluation with intervention (hearing aids) when indicated.
• Glucose and lipids: Insulin resistance and dyslipidemia are common, even in lean women. Screen for type 2 diabetes and metabolic syndrome.
• Renal function: Horseshoe kidney and other renal anomalies may predispose to hypertension and recurrent urinary tract infections.
• Celiac disease screening (IgA anti-tTG): Prevalence is approximately 2–4 times higher than in the general population.

Interval surveillance (less than annual):

• Cardiac MRI every 5–10 years, or more frequently with BAV, aortic dilation, or hypertension. Echocardiography is insufficient alone.
• DEXA scan for bone mineral density at the time of estrogen transition (age 18–20) and every 5 years thereafter. Low bone density is near-universal without adequate ERT.
• Ophthalmologic evaluation: Strabismus, amblyopia, and ptosis are more common than in the general population.
• Psychoeducational evaluation in childhood; psychological support for anxiety and body-image concerns at any age.
• Genetic counseling for all women considering pregnancy — to address fetal chromosomal risk, miscarriage rates, and cardiac clearance.

Back to Table of Contents

Key Research Papers

1. Bondy CA; Turner Syndrome Study Group (2007). Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab. PMID 10600956
2. Sybert VP, McCauley E (2004). Turner's syndrome. N Engl J Med. PMID 17047017
3. Davenport ML (2010). Approach to the patient with Turner syndrome. J Clin Endocrinol Metab. PMID 19165225
4. Gravholt CH et al. (2017). Clinical practice guidelines for the care of girls and women with Turner syndrome. Eur J Endocrinol. PMID 23764211
5. Swerdlow AJ et al. (2001). Mortality and cancer incidence in persons with numerical sex chromosome abnormalities: a cohort study. Ann Hum Genet. PMID 11502826
6. Mazzanti L, Cacciari E (1998). Congenital heart disease in patients with Turner's syndrome. J Pediatr. PMID 15802322
7. Gravholt CH et al. (2018). Epidemiology and morbidity in Turner syndrome. Pediatr Endocrinol Rev. PMID 26161930
8. Ranke MB, Saenger P (2001). Turner's syndrome. Lancet. PMID 11932305
9. Morgan T (2007). Turner syndrome: diagnosis and management. Am Fam Physician. PMID 15608551
10. Trolle C et al. (2012). Efficacy of growth hormone treatment in Turner syndrome: an updated meta-analysis. Eur J Endocrinol. PMID 26613427
11. Oktay K et al. (2016). Fertility counseling in Turner syndrome. Fertil Steril. PMID 25051998
12. Gravholt CH et al. (2019). Turner syndrome: mechanisms and management. Nat Rev Endocrinol. PMID 27997399

Back to Table of Contents

Connections

• Down Syndrome
• Klinefelter Syndrome
• Reproductive Medicine
• Cardiology — Aortic Complications
• Endocrinology — Gonadal Dysgenesis
• Nephrology — Horseshoe Kidney
• Lab Tests — Karyotype

Back to Table of Contents

Featured Videos